Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101

ABSTRACT: The purpose of this study is evaluate the pharmacokinetics, pharmacodynamics, immunogenicity and anti-tumor effect of of fully human anti - VEGF monoclonal antibody LY00101 and explore the potential prognostic and predictive biomarkers. This study will not take into account the results of molecular-genetic tests of patients enrolled in the study

DISEASE(S): Stomach Cancer,Ovarian Cancer,Cervical Cancer,Colorectal Cancer,Stomach Neoplasms

PROVIDER: 2282087 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR